Nature's Sunshine Products Inc. Files Definitive Proxy Statement

Ticker: NATR · Form: DEF 14A · Filed: Mar 15, 2024 · CIK: 275053

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, Corporate Governance, Executive Compensation, Director Election

TL;DR

<b>Nature's Sunshine Products Inc. has filed its Definitive Proxy Statement detailing upcoming shareholder votes on director elections, executive pay, and auditor ratification.</b>

AI Summary

NATURES SUNSHINE PRODUCTS INC (NATR) filed a Proxy Statement (DEF 14A) with the SEC on March 15, 2024. Nature's Sunshine Products Inc. filed a Definitive Proxy Statement (DEF 14A) on March 15, 2024. The filing pertains to the company's 2024 Annual Meeting of Stockholders. Key proposals include the election of directors, an advisory resolution on executive compensation, and ratification of the independent auditor. The document details corporate governance, board structure, director independence, and committee responsibilities. Information on executive compensation, security ownership, and related party transactions is also provided.

Why It Matters

For investors and stakeholders tracking NATURES SUNSHINE PRODUCTS INC, this filing contains several important signals. Shareholders will vote on the election of directors, impacting the company's strategic direction and oversight. The advisory vote on executive compensation allows shareholders to voice their opinion on the company's pay practices for its top executives.

Risk Assessment

Risk Level: low — NATURES SUNSHINE PRODUCTS INC shows low risk based on this filing. The filing is a routine proxy statement, indicating standard corporate governance procedures rather than immediate financial or operational concerns.

Analyst Insight

Review the director nominees and executive compensation proposals to understand potential shifts in corporate strategy and governance.

Key Numbers

Key Players & Entities

FAQ

When did NATURES SUNSHINE PRODUCTS INC file this DEF 14A?

NATURES SUNSHINE PRODUCTS INC filed this Proxy Statement (DEF 14A) with the SEC on March 15, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by NATURES SUNSHINE PRODUCTS INC (NATR).

Where can I read the original DEF 14A filing from NATURES SUNSHINE PRODUCTS INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NATURES SUNSHINE PRODUCTS INC.

What are the key takeaways from NATURES SUNSHINE PRODUCTS INC's DEF 14A?

NATURES SUNSHINE PRODUCTS INC filed this DEF 14A on March 15, 2024. Key takeaways: Nature's Sunshine Products Inc. filed a Definitive Proxy Statement (DEF 14A) on March 15, 2024.. The filing pertains to the company's 2024 Annual Meeting of Stockholders.. Key proposals include the election of directors, an advisory resolution on executive compensation, and ratification of the independent auditor..

Is NATURES SUNSHINE PRODUCTS INC a risky investment based on this filing?

Based on this DEF 14A, NATURES SUNSHINE PRODUCTS INC presents a relatively low-risk profile. The filing is a routine proxy statement, indicating standard corporate governance procedures rather than immediate financial or operational concerns.

What should investors do after reading NATURES SUNSHINE PRODUCTS INC's DEF 14A?

Review the director nominees and executive compensation proposals to understand potential shifts in corporate strategy and governance. The overall sentiment from this filing is neutral.

How does NATURES SUNSHINE PRODUCTS INC compare to its industry peers?

Nature's Sunshine Products Inc. operates in the pharmaceutical preparations industry, as indicated by its SIC code.

Are there regulatory concerns for NATURES SUNSHINE PRODUCTS INC?

The filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

Risk Factors

Industry Context

Nature's Sunshine Products Inc. operates in the pharmaceutical preparations industry, as indicated by its SIC code.

Regulatory Implications

The filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

What Investors Should Do

  1. Review the list of director nominees and their qualifications.
  2. Analyze the details of the executive compensation plan and the advisory resolution.
  3. Examine the ratification proposal for the independent registered public accounting firm.

Key Dates

Glossary

DEF 14A
Definitive Proxy Statement filed with the SEC. (This filing provides detailed information for shareholders regarding company matters to be voted upon at the annual meeting.)
Proxy Statement
A document filed by a company with the SEC that contains information that the shareholders need to vote on company matters. (Essential for shareholders to make informed decisions on proposals such as director elections and executive compensation.)

Year-Over-Year Comparison

This is a new filing (DEF 14A) and does not have a direct prior filing to compare against for 'vs last filing' data.

Filing Stats: 4,340 words · 17 min read · ~14 pages · Grade level 14.8 · Accepted 2024-03-15 09:14:31

Key Financial Figures

Filing Documents

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 59 Board Leadership and Diversity 19 Nominees for Election 21 Delinquent Section 16(a) Reports 61 Director Compensation 26 Equity Compensation Plans 61 Questions and Answers about the 2023 Annual Meeting and this Proxy Statement 62 Executive Officers 29 Householding of Proxy Materials 65

Executive Compensation

Executive Compensation 32 Other Matters 65 Narrative Discussion of Compensation Policies 33 Summary Compensation Table 43 Outstanding Equity Awards at Year-End 44 Pay versus Performance 46 Potential Payments Upon Termination or Change in Control 49 Certain information included or incorporated herein by reference in this document may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. All forward-looking statements speak only as of the date of this document and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into annual report on Form 10-K filed with the SEC on March 12, 2024. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this document. Throughout this document, we refer to Nature's Sunshine Products, Inc., together with our subsidiaries, as Nature's Sunshine, "we," "us," "our," "our Company" or "the Company." Letter from our President and Chief Executive Officer Dear Fellow Shareholder I invite you to attend the 2024 Natu

Executive Compensation Highlights

Executive Compensation Highlights Obtaining and retaining a talented and experienced leadership team is key to our long term success. Our Compensation Committee has designed an effective compensation program, following important policies and best practices, in order to achieve this objective. Our named executive officer (NEO) compensation packages primarily consists of three elements (i) a base salary, (ii) annual cash incentive based upon overall Company or segment financial performance, and (iii) participation in long-term, stock-based incentive awards, in the form of restricted stock units (RSUs) and performance-contingent RSUs (PRSUs). In 2023, we did not make significant changes to our executive compensation with it being the first full year of employment for all NEOs except Mr. Moorehead. Our performance in 2023 produced positive outcomes on all fronts, highlighted by strong fundamental growth in key markets and significant results from our profitability measures. Despite continued inflationary pressures and significant foreign exchange impacts, we managed to record overall net sales and net income gains. All of these impacted our results and performance, and in turn, our executive compensation. 2023 Performance-based Results Performance-based incentives paid to our NEOs in 2023 reflected our continued focus to take our Company to the next level. Annual Cash Incentive Our 2023 corporate revenue and adjusted EBITDA performance exceeded targets, resulting in a 2023 Annual Cash Incentive payout of 160%. Performance-based RSUs In 2023, PRSUs were granted and contingent on rolling four-quarter adjusted EBITDA, which if achieved would evidence strong overall growth to our top and bottom line. Early 2024 Compensation Decisions Based on a 94.3 percent vote of favorable shareholder approval in 2023, the Compensation Committee decided not to make any material changes to our compensation philosophies, policies and practices in 2024. In early 2024 our Co

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing